Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 11/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.44 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993811 | 0.83 | MAPK14 (0.48) | XPO1HTTKMT2AIGF1RJAK3 | |
| SCHEMBL2848264 | 0.81 | XPO1 (0.54) | XPO1GSK3BMEN1HTTKMT2A | |
| SCHEMBL3989131 | 0.77 | TNIK (0.50) | NPC1RAB9A | |
| SCHEMBL3992045 | 0.77 | XPO1 (0.46) | XPO1HTTKMT2ANPC1RAB9A | |
| SCHEMBL1702491 | 0.76 | XPO1 (0.49) | XPO1MEN1HTTKMT2ALCK | |
| SCHEMBL25853864 | 0.75 | XPO1 (0.48) | XPO1GSK3BMEN1HTTKMT2A | |
| SCHEMBL1702275 | 0.75 | MDM2 (0.48) | XPO1GSK3BMEN1HTTKMT2A | |
| SCHEMBL29568127 | 0.74 | XPO1 (0.50) | XPO1MEN1HTTKMT2ALCK | |
| SCHEMBL29110574 | 0.74 | NFKB1 (0.51) | XPO1NPC1RAB9A | |
| SCHEMBL1702529 | 0.74 | XPO1 (0.47) | XPO1HTTKMT2AABL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1781637-A1 | 2-SUBSTITUTED QUINOLINE COMPOUNDS AND THEIR USES AS INHIBITORS OF THE IGE RECEPTOR SIGNALING CASCADE | Rigel Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060040982-A1 | 2-Substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| WO-2006004865-A1 | 2-SUBSTITUTED QUINOLINE COMPOUNDS AND THEIR USES AS INHIBITORS OF THE IGE RECEPTOR SIGNALING CASCADE | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040982-A1 | 2-Substituted quinoline compounds and their uses | FCER2, LTB4R2, CYSLTR2 | XPO1 2363/4885AURKA 2835/4885GSK3B 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.